P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Figure 2

Changes in P2Y12 inhibitor use through the study period between 2021 and 2018. Trends over time was evaluated using the Cochran–Mantel–Haenszel test with  < 0.001.